Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Aldo Scarpa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1678-739X; OpenAlex author ID A5003507376. Sources: OpenAlex.

Their work

Papers
130 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
418
Papers, trials and grants by year

2011: 6 papers · 2012: 5 papers · 2013: 4 papers · 2014: 5 papers · 2015: 6 papers · 2016: 12 papers · 2017: 9 papers · 2018: 8 papers · 2019: 8 papers · 2020: 8 papers · 2021: 14 papers · 2022: 8 papers · 2023: 14 papers · 2024: 9 papers · 2025: 8 papers · 2026: 6 papers

Papers 50 of 130

  1. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation … Co-author DOI 10.1016/j.humpath.2025.106014↗
  2. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  3. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  4. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  5. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  6. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  7. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  8. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  9. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  10. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  11. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41419-025-08082-1↗
  12. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  13. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  14. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  15. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. Co-author DOI 10.1002/1878-0261.13658↗
  16. A Self-Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1002/adhm.202301941↗
  17. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  18. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.immuni.2024.04.021↗
  19. The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41417-024-00814-3↗
  20. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  21. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  22. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  23. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Co-author DOI 10.1186/s13148-024-01623-z↗
  24. Dissecting the role of toll-like receptor 7 in pancreatic cancer. Co-author DOI 10.1002/cam4.5606↗
  25. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  26. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  27. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  28. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Co-author DOI 10.1038/s41416-022-02028-6↗
  29. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  30. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  31. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-325117↗
  32. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology. Co-author DOI 10.1136/jcp-2023-209012↗
  33. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth. Co-author DOI 10.1158/1078-0432.ccr-22-0794↗
  34. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
  35. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  36. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  37. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. Co-author DOI 10.3390/cancers15051454↗
  38. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Last author DOI 10.1007/s00428-021-03205-3↗
  39. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  40. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Last author DOI 10.1016/s1470-2045(22)00448-x↗
  41. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  42. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Co-author DOI 10.1080/14728222.2022.2021397↗
  43. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  44. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  45. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  46. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Co-author DOI 10.1038/s41467-021-25921-9↗
  47. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  48. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-021-00192-1↗
  49. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  50. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Co-author DOI 10.1073/pnas.2020395118↗

Closest collaborators

The 25 strongest of 418 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rita Teresa Lawlor · 47 shared papers, 2012–2026 · strength 5.64
  2. Claudio Luchini · 36 shared papers, 2016–2026 · strength 5.03
  3. Roberto Salvia · 32 shared papers, 2017–2026 · strength 4.17
  4. Giuseppe Malleo · 25 shared papers, 2016–2026 · strength 3.24
  5. Vincenzo Corbo · 22 shared papers, 2012–2025 · strength 2.60
  6. Claudio Bassi · 25 shared papers, 2011–2025 · strength 2.19
  7. Michèle Milella · 20 shared papers, 2011–2025 · strength 2.12
  8. Antonio Pea · 15 shared papers, 2018–2026 · strength 2.04
  9. Paola Mattiolo · 11 shared papers, 2020–2026 · strength 1.75
  10. Salvatore Paiella · 12 shared papers, 2018–2026 · strength 1.60
  11. Andrea Mafficini · 11 shared papers, 2011–2025 · strength 1.36
  12. Matteo Fassan · 12 shared papers, 2014–2026 · strength 1.27
  13. Gabriella Lionetto · 7 shared papers, 2022–2026 · strength 1.21
  14. Carmine Carbone · 9 shared papers, 2017–2025 · strength 1.13
  15. Laura Maggino · 9 shared papers, 2017–2023 · strength 1.08
  16. Geny Piro · 9 shared papers, 2017–2025 · strength 1.07
  17. Thomas Mathias Gress · 11 shared papers, 2014–2025 · strength 0.99
  18. Alessandro Esposito · 6 shared papers, 2018–2026 · strength 0.95
  19. Francesco De Sanctis · 7 shared papers, 2019–2025 · strength 0.91
  20. Eithne Costello · 15 shared papers, 2013–2024 · strength 0.90
  21. Giovanni Marchegiani · 9 shared papers, 2017–2024 · strength 0.88
  22. Pietro Delfino · 7 shared papers, 2019–2024 · strength 0.87
  23. Andrew Victor Biankin · 9 shared papers, 2014–2023 · strength 0.83
  24. Francesca Lupo · 6 shared papers, 2019–2025 · strength 0.83
  25. Núria Malats · 9 shared papers, 2017–2025 · strength 0.79

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.